Millennium Management’s Filana Therapeutics FLNA Stock Holding History

Millennium Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-90,900	Closed	-$215K	–	6340
2024 Q4	$215K	Buy	+90,900	New	+$1.6M	﹤0.01%	5273
2021 Q2	–	Sell	-20,000	Closed	-$899K	–	7039
2021 Q1	$899K	Buy	+20,000	New	+$787K	﹤0.01%	4327

Other funds holding FLNA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Millennium Management's FLNA Position: Q2 2026 in Review

Millennium Management sold out of Filana Therapeutics (FLNA) in Q2 2026, closing a stake of 72,588 shares — an estimated $123K sold.

Millennium Management first reported a position in FLNA in Q2 2013 and held it in 23 quarters. The position peaked at $10.3M in Q1 2021. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

Millennium Management reported no remaining Filana Therapeutics position as of Q2 2026 after selling out during the quarter.
Millennium Management sold 72,588 Filana Therapeutics shares in Q2 2026, an estimated $123K.
Millennium Management first reported a position in Filana Therapeutics in Q2 2013 and held it in 23 quarters.
Millennium Management's Filana Therapeutics position peaked at $10.3M in Q1 2021.
84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.